HomeCompareTIHRF vs PFE

TIHRF vs PFE: Dividend Comparison 2026

TIHRF yields 2.04% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TIHRF wins by $69.63M in total portfolio value
10 years
TIHRF
TIHRF
● Live price
2.04%
Share price
$1.37
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.68M
Annual income
$63,674,902.73
Full TIHRF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TIHRF vs PFE

📍 TIHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTIHRFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TIHRF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TIHRF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TIHRF
Annual income on $10K today (after 15% tax)
$173.28/yr
After 10yr DRIP, annual income (after tax)
$54,123,667.32/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TIHRF beats the other by $54,101,347.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TIHRF + PFE for your $10,000?

TIHRF: 50%PFE: 50%
100% PFE50/50100% TIHRF
Portfolio after 10yr
$34.86M
Annual income
$31,850,580.72/yr
Blended yield
91.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TIHRF
No analyst data
Altman Z
3.2
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TIHRF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTIHRFPFE
Forward yield2.04%6.13%
Annual dividend / share$0.03$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$69.68M$49.6K
Annual income after 10y$63,674,902.73$26,258.71
Total dividends collected$69.19M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TIHRF vs PFE ($10,000, DRIP)

YearTIHRF PortfolioTIHRF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,108$407.72$9,153$693.39+$2.0KTIHRF
2$12,732$846.52$8,593$849.25+$4.1KTIHRF
3$15,437$1,813.63$8,336$1,066.78+$7.1KTIHRF
4$20,627$4,110.16$8,437$1,384.80+$12.2KTIHRF
5$32,337$10,265.86$9,013$1,875.40+$23.3KTIHRF
6$64,682$30,081.50$10,306$2,680.72+$54.4KTIHRF
7$181,678$112,468.06$12,820$4,101.38+$168.9KTIHRF
8$784,859$590,463.23$17,673$6,826.70+$767.2KTIHRF
9$5,607,709$4,767,910.43$27,543$12,591.86+$5.58MTIHRF
10$69,675,152$63,674,902.73$49,560$26,258.71+$69.63MTIHRF

TIHRF vs PFE: Complete Analysis 2026

TIHRFStock

Tharisa plc, an investment holding company, engages in the mining, processing, beneficiation, marketing, sale, and logistics of platinum group metals (PGM) and chrome concentrates in South Africa, China, Singapore, Hong Kong, Australia, Japan, and internationally. It operates through four segments: PGM, Chrome, Agency and Trading, and Manufacturing. The company's PGM basket includes platinum, palladium, rhodium, gold, ruthenium, iridium, nickel, and copper. It holds 100% interest in the Tharisa mine, an open pit PGM and chrome mine located on the south-western limb of the Bushveld Complex, South Africa. The company also offers chemical and foundry grade chrome concentrates; and metallurgical grade chrome concentrate for stainless steel and ferrochrome producers, as well as commodity traders. In addition, it is involved the manufacturing of mining equipment. The company was incorporated in 2008 and is based in Paphos, Cyprus.

Full TIHRF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TIHRF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TIHRF vs SCHDTIHRF vs JEPITIHRF vs OTIHRF vs KOTIHRF vs MAINTIHRF vs JNJTIHRF vs MRKTIHRF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.